Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

…, LM Schuchter, H Ishwaran, R Mick, DA Pryma… - Nature, 2015 - nature.com
Immune checkpoint inhibitors 1 result in impressive clinical responses 2 , 3 , 4 , 5 , but
optimal results will require combination with each other 6 and other therapies. This raises …

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a …

…, S Ruan, C Pierre, A Nagel, DA Pryma… - The lancet …, 2007 - thelancet.com
Background Preoperative identification of tumour type could have important implications for
the choice of treatment for renal cancers. Antibody cG250 reacts against carbonic anhydrase-…

Making molecular imaging a clinical tool for precision oncology: a review

DA Mankoff, MD Farwell, AS Clark, DA Pryma - JAMA oncology, 2017 - jamanetwork.com
Importance Individualized cancer treatment, tailored to a particular patient and the tumor’s
biological features (precision oncology), requires a detailed knowledge of tumor biology. …

Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma

DA Pryma, BB Chin, RB Noto, JS Dillon… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma
(PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial …

[HTML][HTML] A PET imaging agent for evaluating PARP-1 expression in ovarian cancer

…, R Doot, MD Farwell, DA Pryma… - The Journal of …, 2018 - Am Soc Clin Investig
BACKGROUND. Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in a broad
population of patients with ovarian cancer; however, resistance caused by low enzyme …

124I-huA33 antibody PET of colorectal cancer

…, PM Smith-Jones, CR Divgi, DA Pryma… - Journal of Nuclear …, 2011 - Soc Nuclear Med
Humanized A33 (huA33) is a promising monoclonal antibody that recognizes A33 antigen,
which is present in more than 95% of colorectal cancers and in normal bowel. In this study, …

The nuclear receptor Rev-erbα controls circadian thermogenic plasticity

…, A Bugge, C Hou, C Ferrara, P Seale, DA Pryma… - Nature, 2013 - nature.com
Circadian oscillation of body temperature is a basic, evolutionarily conserved feature of
mammalian biology 1 . In addition, homeostatic pathways allow organisms to protect their core …

PET/CT imaging in cancer: current applications and future directions

MD Farwell, DA Pryma, DA Mankoff - Cancer, 2014 - Wiley Online Library
Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative
images of regional in vivo biology and biochemistry. PET, now used in conjunction with …

Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients

DA Pryma, H Schöder, M Gönen… - Journal of Nuclear …, 2006 - Soc Nuclear Med
Hürthle cell carcinoma is an uncommon and occasionally aggressive differentiated thyroid
cancer associated with increased mortality compared with other differentiated thyroid …

PennPET explorer: human imaging on a whole-body imager

…, G Muehllehner, MJ Parma, DA Pryma… - Journal of Nuclear …, 2020 - Soc Nuclear Med
The PennPET Explorer, a prototype whole-body imager currently operating with a 64-cm axial
field of view, can image the major body organs simultaneously with higher sensitivity than …